CSIMarket Company Name, Ticker, Competitors, else..
 
Alzamend Neuro Inc   (NASDAQ: ALZN)
 
Price: $1.7800 $0.03 1.714%
Day's High: $1.7899999618530273 Week Perf: 5.95 %
Day's Low: $ 1.73 30 Day Perf: 14.84 %
Volume (M): 228,431 52 Wk High: $ 2.68
Volume (M$): $ 0 52 Wk Avg: $1.75
Open: $1.75 52 Wk Low: $0.84



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 4
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 1

Business Description


Alzamend Neuro Inc is a biotechnology company focused on the development of innovative therapies and diagnostic tools for Alzheimer's disease. The company aims to address the significant unmet medical needs in Alzheimer's disease by advancing novel drug candidates and diagnostic biomarkers. Alzamend Neuro is committed to improving the quality of life for Alzheimer's patients and their families by providing better treatment options and accurate diagnostic tools. They are actively involved in research, development, and clinical trials to bring new solutions for Alzheimer's disease.


   Company Address: 3480 Peachtree Road NE Atlanta 30326 GA
   Company Phone Number: 722-6303   Stock Exchange / Ticker: NASDAQ ALZN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATAI        0.14% 
BMY   -1.48%    
INDV   -0.29%    
JNJ   -0.71%    
LLY        1.09% 
PFE   -0.86%    
• View Complete Report
   



Business Update

Alzamend Neuro Collaborates with Massachusetts General Hospital for Pioneering Phase II Trial of AL001 in PTSD Treatm...

Published Mon, Aug 19 2024 12:47 PM UTC

Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company, has announced a significant partnership with Massachusetts General Hospital (MGH) to initiate a Phase II clinical trial for AL001, a next-generation lithium therapeutic candidate. This trial aims to explore the efficacy of AL001 in patients suffering from post-traumatic stress disorder (PTSD), m...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.37
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.77
Working Capital Ratio 2.77
Leverage Ratio (MRQ) 0.47
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.42 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 1.7 $
Book Value 1.3 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,516,117
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.